Current clinical trial design issues in hormone-refractory prostate carcinoma
Open Access
- 1 June 1998
- Vol. 82 (11) , 2093-2101
- https://doi.org/10.1002/(sici)1097-0142(19980601)82:11<2093::aid-cncr3>3.0.co;2-x
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- An adjustment to the 1997 estimate for new prostate cancer cases.CA: A Cancer Journal for Clinicians, 1997
- Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.Journal of Clinical Oncology, 1997
- Cancer statistics, 1996CA: A Cancer Journal for Clinicians, 1996
- Treatment plans for black and white women with stage II node-positive breast cancer: The national cancer institute black/white cancer survival study experienceCancer, 1992
- Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer: A hoosier oncology group studyCancer, 1992
- Cancer statistics, 1991CA: A Cancer Journal for Clinicians, 1991
- Chemotherapy Programs of the National Prostatic Cancer Project (NPCP)Cancer, 1980
- Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer. A randomized trialCancer, 1978
- Chemotherapy of advanced prostatic cancer Evaluation of response parametersUrology, 1976
- Chemotherapy of Advanced Prostatic Carcinoma with Cyclophosphamide or 5-Fluorouracil: Results of First National Randomized StudyJournal of Urology, 1975